Doxycycline for Legionella Pneumonia: Expanding Treatment Horizons Through a Case Series and Narrative Review
Abstract
Background: Legionella pneumonia is a significant cause of community-acquired pneumonia that often requires timely and effective treatment. While fluoroquinolones and macrolides are the recommended first-line therapies, doxycycline offers an alternative with favorable pharmacokinetics, safety, and minimal drug-drug interactions. Methods: We describe three hospitalized patients with Legionella pneumonia who received doxycycline monotherapy.Clinical outcomes, including symptom resolution and survival, were assessed at 60 days. A literature review was also performed for studies published between 1980 and 2025 that evaluated doxycycline for Legionella infection. Results: All three patients achieved clinical improvement with doxycycline monotherapy, with resolution of presenting symptoms and survival at 60 days post-hospitalization. The literature review identified limited clinical data on doxycycline for Legionella pneumonia. In vitro data suggested that doxycycline may have lower bactericidal activity than fluoroquinolones, although its pharmacological profile and tolerability support its consideration in select cases. Conclusion: Doxycycline monotherapy was associated with favorable outcomes in three cases of Legionella pneumonia. Although the evidence remains sparse, doxycycline may represent a viable alternative when first-line therapy is contraindicated. Further research is required to define its role in the treatment of Legionella pneumonia.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.